₹1427.3
-21.3 (-1.47%) - 19 May 2025 02:53 PMGlenmark Pharmaceuticals Limited is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.
Industry - Pharmaceuticals & Drugs
* Please refer to the Standalone data if Consolidated financial data for the company is not available.
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED
| All logos and Trademarks registered with their respective owners.
